HK1165955A1 - Purification of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine 1-[2-(24-)] - Google Patents

Purification of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine 1-[2-(24-)]

Info

Publication number
HK1165955A1
HK1165955A1 HK12106536.4A HK12106536A HK1165955A1 HK 1165955 A1 HK1165955 A1 HK 1165955A1 HK 12106536 A HK12106536 A HK 12106536A HK 1165955 A1 HK1165955 A1 HK 1165955A1
Authority
HK
Hong Kong
Prior art keywords
dimethylphenylsulfanyl
piperazine
purification
phenyl
Prior art date
Application number
HK12106536.4A
Other languages
English (en)
Chinese (zh)
Inventor
Henrik Vigan Nicolajsen
De Diego Heidi Lopez
Michael Harold Rock
Original Assignee
.隆德貝克有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by .隆德貝克有限公司 filed Critical .隆德貝克有限公司
Publication of HK1165955A1 publication Critical patent/HK1165955A1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/096Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/02Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
    • C07D295/027Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
HK12106536.4A 2009-02-17 2012-07-04 Purification of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine 1-[2-(24-)] HK1165955A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200900223 2009-02-17
PCT/DK2010/050039 WO2010094285A1 (en) 2009-02-17 2010-02-16 Purification of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine

Publications (1)

Publication Number Publication Date
HK1165955A1 true HK1165955A1 (en) 2012-10-12

Family

ID=42101395

Family Applications (1)

Application Number Title Priority Date Filing Date
HK12106536.4A HK1165955A1 (en) 2009-02-17 2012-07-04 Purification of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine 1-[2-(24-)]

Country Status (28)

Country Link
US (1) US8598348B2 (ru)
EP (1) EP2398785B1 (ru)
JP (1) JP5738774B2 (ru)
KR (1) KR101639833B1 (ru)
CN (1) CN102317272B (ru)
AR (1) AR075436A1 (ru)
AU (1) AU2010214956B2 (ru)
BR (1) BRPI1006975B1 (ru)
CA (1) CA2751498C (ru)
CL (1) CL2011001992A1 (ru)
CO (1) CO6400224A2 (ru)
DK (1) DK2398785T3 (ru)
EA (1) EA020473B1 (ru)
ES (1) ES2441079T3 (ru)
HK (1) HK1165955A1 (ru)
HR (1) HRP20131236T1 (ru)
IL (1) IL214178A (ru)
MX (1) MX2011008661A (ru)
NZ (1) NZ594658A (ru)
PL (1) PL2398785T3 (ru)
PT (1) PT2398785E (ru)
RS (1) RS53074B (ru)
SG (1) SG173735A1 (ru)
SI (1) SI2398785T1 (ru)
SM (1) SMT201400010B (ru)
TW (1) TW201033181A (ru)
WO (1) WO2010094285A1 (ru)
ZA (1) ZA201105992B (ru)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2800746T (lt) * 2012-01-03 2019-06-10 H. Lundbeck A/S 1-[2-(2,4-dimetil-fenilsulfanil)-fenil]-piperazino gavimo būdas
WO2014044721A1 (en) 2012-09-19 2014-03-27 Sandoz Ag Novel crystalline form of vortioxetine hydrobromide
ES2663680T3 (es) 2012-12-13 2018-04-16 H. Lundbeck A/S Composiciones que comprenden vortioxetina y donepezilo
RU2652265C2 (ru) * 2013-02-22 2018-04-27 Х. Лундбекк А/С Способ получения вортиоксетина
WO2015035802A1 (zh) * 2013-09-12 2015-03-19 杭州普晒医药科技有限公司 沃替西汀盐及其晶体、它们的制备方法、药物组合物和用途
IN2013MU03121A (ru) * 2013-09-30 2015-07-17 Cadila Healthcare Ltd
EP2878596A1 (en) * 2013-11-29 2015-06-03 LEK Pharmaceuticals d.d. Synthesis of vortioxetine via (2-(piperazine-1-yl)phenyl)lithium intermediates
CN103788019B (zh) * 2014-01-22 2015-10-07 苏州明锐医药科技有限公司 沃替西汀的制备方法
CN103788020B (zh) * 2014-01-22 2015-11-04 苏州明锐医药科技有限公司 沃替西汀的制备方法
EA029060B1 (ru) 2014-01-31 2018-02-28 Эгиш Дьёдьсердьяр Зрт. Способ получения солей вортиоксетина
CN104059030B (zh) * 2014-05-30 2016-05-04 镇江圣安医药有限公司 [(苯硫烷基)-苯基]哌嗪的衍生物及其药物组合物和用途
CN105218482B (zh) * 2014-06-24 2018-04-06 杭州和泽医药科技有限公司 沃替西汀氢溴酸盐β晶型的制备方法
US9687484B2 (en) 2014-07-18 2017-06-27 Dipharma Francis S.R.L. Crystalline forms of an antidepressant compound
WO2016079751A2 (en) 2014-11-17 2016-05-26 Megafine Pharma (P) Ltd. A process for preparation of vortioxetine and polymorphs thereof
CN105669594A (zh) * 2014-11-19 2016-06-15 康普药业股份有限公司 抗抑郁症药1-[2-(2,4-二甲基苯基硫基)苯基]哌嗪的制备方法
CN105801517A (zh) * 2014-12-30 2016-07-27 上海奥博生物医药技术有限公司 一种沃替西汀氢溴酸盐新晶型及其制备方法
WO2016125190A2 (en) 2015-02-04 2016-08-11 Mylan Laboratories Limited Novel crystalline forms of vortioxetine, premixes, and processes for the preparation thereof
WO2016151328A1 (en) 2015-03-26 2016-09-29 Cipla Limited Method for making serotonin reuptake inhibitors
CN105367515B (zh) * 2015-05-08 2017-10-27 北京北陆药业股份有限公司 一种氢溴酸沃替西汀α晶型的制备方法
CN105439980B (zh) * 2015-05-08 2017-10-24 北京北陆药业股份有限公司 一种氢溴酸沃替西汀一仲丁醇合物及其制备方法
CN106316985B (zh) * 2015-06-18 2021-11-09 郑州深蓝海生物医药科技有限公司 一种β型高效氢溴酸沃替西汀转晶方法
WO2017125504A1 (en) * 2016-01-20 2017-07-27 Amneal Pharmaceuticals Company Gmbh Polymorphic forms of vortioxetine hydrobromide tert-butanolate
CN109310691A (zh) 2016-07-01 2019-02-05 H.隆德贝克有限公司 用于快速开始抗抑郁作用的给药方案
US10519121B2 (en) 2016-12-30 2019-12-31 Apicore Us Llc Process and novel polymorphic form of vortioxetine and its pharmaceutically acceptable salts
HRP20220108T1 (hr) * 2017-04-25 2022-04-15 H. Lundbeck A/S Postupak za proizvodnju vortioksetina hbr alfa-oblika
CN108017595A (zh) * 2017-12-20 2018-05-11 安徽源久源科技有限公司 一种1-[2-(2,5-二甲基苯硫基)苯基]哌嗪的制备方法
CN112125868B (zh) * 2020-09-25 2021-08-03 中山万远新药研发有限公司 一种氢溴酸伏硫西汀晶型及其制备方法、组合物与用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB852974A (en) 1958-04-17 1960-11-02 Parke Davis & Co Ethers and means for producing the same
FR2186237B1 (ru) 1972-05-03 1975-10-31 Synthelabo
US5576460A (en) 1994-07-27 1996-11-19 Massachusetts Institute Of Technology Preparation of arylamines
UA81749C2 (ru) * 2001-10-04 2008-02-11 Х. Луннбек А/С производные фенилпиперазина как ингибиторы обратного захвата серотонинА
CN102614179B (zh) * 2006-06-16 2015-11-25 H.隆德贝克有限公司 作为用于治疗认知损伤的、具有结合的对血清素再吸收、5-ht3和5-ht1a活性的化合物的1-[2-(2,4-二甲基苯基硫烷基)-苯基]哌嗪
AU2007260356B2 (en) * 2006-06-16 2013-01-24 H. Lundbeck A/S Crystalline forms of 4- [2- (4-methylphenylsulfanyl) -phenyl] piperidine with combined serotonin and norepinephrine reuptake inhibition for the treatment of neuropathic pain
TW200848411A (en) 2007-03-20 2008-12-16 Lundbeck & Co As H Novel therapeutic uses of 1-[2-(2, 4-dimethylphenylsulfanyl)phenyl]-piperazine

Also Published As

Publication number Publication date
IL214178A (en) 2014-09-30
US8598348B2 (en) 2013-12-03
CA2751498A1 (en) 2010-08-26
DK2398785T3 (da) 2013-12-16
SG173735A1 (en) 2011-09-29
MX2011008661A (es) 2011-09-06
PT2398785E (pt) 2013-12-26
EA020473B1 (ru) 2014-11-28
NZ594658A (en) 2013-02-22
JP2012517961A (ja) 2012-08-09
TW201033181A (en) 2010-09-16
BRPI1006975B1 (pt) 2022-11-22
EP2398785A1 (en) 2011-12-28
EP2398785B1 (en) 2013-11-27
HRP20131236T1 (hr) 2014-02-14
SMT201400010B (it) 2014-03-07
CN102317272A (zh) 2012-01-11
AU2010214956A1 (en) 2011-09-22
ZA201105992B (en) 2012-10-31
KR20110126625A (ko) 2011-11-23
IL214178A0 (en) 2011-08-31
CO6400224A2 (es) 2012-03-15
PL2398785T3 (pl) 2014-07-31
AR075436A1 (es) 2011-03-30
CL2011001992A1 (es) 2012-04-09
RS53074B (en) 2014-04-30
WO2010094285A1 (en) 2010-08-26
SI2398785T1 (sl) 2014-01-31
KR101639833B1 (ko) 2016-07-14
CN102317272B (zh) 2014-11-12
ES2441079T3 (es) 2014-01-31
BRPI1006975A2 (pt) 2020-08-18
US20120004409A1 (en) 2012-01-05
CA2751498C (en) 2017-09-12
EA201171065A1 (ru) 2012-02-28
AU2010214956B2 (en) 2012-08-23
JP5738774B2 (ja) 2015-06-24

Similar Documents

Publication Publication Date Title
HK1165955A1 (en) Purification of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine 1-[2-(24-)]
IL238068A0 (en) New therapeutic uses of 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine
ZA201107731B (en) Liquid formulations of salts of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine
HRP20130819T1 (en) New compositions of 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]piperazine
IL201533A0 (en) Novel piperazine salts as d3/d2 antagonists
IL244059A0 (en) Phenoxymethyl heterocyclic compounds
IL202666A0 (en) Substituted piperazines
IL217927A0 (en) Novel azaheterocyclic compounds
AP3583A (en) Therapeutic uses of 1-[2-(2,4-dimethyl-phenylsulfanyl)phenyl]piperazine
GB0919816D0 (en) Heterocyclic compounds
GB0919817D0 (en) Heterocyclic compounds
GB0900392D0 (en) New compounds 2